Equity Profile

LLY

Eli Lilly and Company

Health CarePharmaceuticals$1.1T

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Eli Lilly and Company (LLY) is a leading pharmaceutical company focused on developing innovative treatments for various health conditions, including diabetes and cancer. With a market cap of $1,078 billion, it plays a crucial role in the healthcare sector, addressing significant medical needs and contributing to advancements in patient care.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and is closely watched by investors.

$6.55

Revenue

Revenue growth reflects the company's ability to sell its products and expand its market share.

$20.7B

Wall Street expectations, options signals, track record, and call prep available with Pro.

LLY Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+10.79%

Avg Stock Reaction

+0.58%

Last Quarter Recap

In Q1 2026, Eli Lilly reported an EPS of $8.55, significantly exceeding analyst expectations of $7.06, resulting in a 9.80% stock increase the following day. The company continues to show strong performance, indicating robust demand for its products.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are optimistic about Eli Lilly's upcoming earnings report, with expectations for strong EPS and revenue figures. The company has a history of beating estimates, which could lead to positive market reactions.

Bull Case

If Eli Lilly surpasses the consensus EPS of $6.55 and reports strong revenue, it could reinforce investor confidence and drive the stock higher.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a significant decline in stock price, reflecting investor disappointment.

Key Metrics to Watch

Earnings Per Share (EPS)

$6.55

EPS is a key indicator of the company's profitability and is closely watched by investors.

Revenue

$20.7B

Revenue growth reflects the company's ability to sell its products and expand its market share.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Eli Lilly's EPS exceed the consensus estimate of $6.55?

A strong EPS report could validate the company's growth strategy and boost investor confidence.

What guidance will management provide regarding future revenue growth?

Future revenue guidance is crucial for understanding the company's trajectory and market positioning.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Eli Lilly's ability to leverage its recent product launches, which could drive stronger-than-expected revenue growth.

Supporting Evidence

The company's recent performance has shown a consistent ability to exceed EPS estimates, suggesting strong operational execution.

Options pricing indicates a significant expected move, reflecting market anticipation that could be based on positive developments not yet fully appreciated.

Historically, Eli Lilly has a 75% EPS beat rate, indicating a strong track record of outperforming expectations.

Key Risk

If the upcoming report reveals lower-than-expected demand for key products, it could challenge the current bullish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will determine whether Eli Lilly can maintain its growth momentum amid increasing competition.

Bull Confirmed If

A reported EPS of $7.00 or higher would confirm the bull case.

Bear Confirmed If

An EPS below $5.50 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±8.56%

Historical Avg

±8.6%

In line with history

The options market is pricing in an 8.56% move, indicating that traders expect significant volatility around the earnings report.

Options are pricing ±8.6% while LLY has averaged ±8.6% over the last 8 prints — setup is roughly in line with history.

Detail

ATM IV

0.4%

30d HV

41.6%

Calls (3.2M)P/C Ratio: 0.97Puts (1.4M)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Eli Lilly beats expectations, history suggests a potential 3.77% increase in stock price, confirming the company's strong growth narrative.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further clarity from management.

Miss

Should the company miss estimates, history indicates an average decline of 8.97%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their market reception.
2Management's commentary on competitive pressures and pricing strategies.
3Insights into research and development progress for upcoming therapies.
4Guidance on revenue expectations for the next quarter and beyond.
5Any changes in regulatory environment affecting product approvals.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and is closely watched by investors.

$6.55

Revenue

Revenue growth reflects the company's ability to sell its products and expand its market share.

$20.7B

Wall Street expectations, options signals, track record, and call prep available with Pro.

LLY Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+10.79%

Avg Stock Reaction

+0.58%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Eli Lilly surpasses the consensus EPS of $6.55 and reports strong revenue, it could reinforce investor confidence and drive the stock higher.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a significant decline in stock price, reflecting investor disappointment.

Key Metrics to Watch

Earnings Per Share (EPS)

$6.55

EPS is a key indicator of the company's profitability and is closely watched by investors.

Revenue

$20.7B

Revenue growth reflects the company's ability to sell its products and expand its market share.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Eli Lilly's EPS exceed the consensus estimate of $6.55?

A strong EPS report could validate the company's growth strategy and boost investor confidence.

What guidance will management provide regarding future revenue growth?

Future revenue guidance is crucial for understanding the company's trajectory and market positioning.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Eli Lilly's ability to leverage its recent product launches, which could drive stronger-than-expected revenue growth.

Supporting Evidence

The company's recent performance has shown a consistent ability to exceed EPS estimates, suggesting strong operational execution.

Options pricing indicates a significant expected move, reflecting market anticipation that could be based on positive developments not yet fully appreciated.

Historically, Eli Lilly has a 75% EPS beat rate, indicating a strong track record of outperforming expectations.

Key Risk

If the upcoming report reveals lower-than-expected demand for key products, it could challenge the current bullish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will determine whether Eli Lilly can maintain its growth momentum amid increasing competition.

Bull Confirmed If

A reported EPS of $7.00 or higher would confirm the bull case.

Bear Confirmed If

An EPS below $5.50 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±8.56%

Historical Avg

±8.6%

In line with history

The options market is pricing in an 8.56% move, indicating that traders expect significant volatility around the earnings report.

Options are pricing ±8.6% while LLY has averaged ±8.6% over the last 8 prints — setup is roughly in line with history.

Detail

ATM IV

0.4%

30d HV

41.6%

Calls (3.2M)P/C Ratio: 0.97Puts (1.4M)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Eli Lilly beats expectations, history suggests a potential 3.77% increase in stock price, confirming the company's strong growth narrative.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further clarity from management.

Miss

Should the company miss estimates, history indicates an average decline of 8.97%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their market reception.
2Management's commentary on competitive pressures and pricing strategies.
3Insights into research and development progress for upcoming therapies.
4Guidance on revenue expectations for the next quarter and beyond.
5Any changes in regulatory environment affecting product approvals.